Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
about
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza VaccinesMeasuring Cellular Immunity to Influenza: Methods of Detection, Applications and ChallengesRecent advances in the development of vaccines for tuberculosisAdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human PrimatesAge at Mycobacterium bovis BCG Priming Has Limited Impact on Anti-Tuberculosis Immunity Boosted by Respiratory Mucosal AdHu5Ag85A Immunization in a Murine ModelThe effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis VaccinesRecombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy AdultsA Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored VaccinesEvaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Tuberculosis vaccine development: Shifting focus amid increasing development challenges.Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85ABCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.Current status of new tuberculosis vaccine in children.Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populationsAerosol immunisation for TB: matching route of vaccination to route of infectionModified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.A review of clinical models for the evaluation of human TB vaccines.The long and winding road to inhaled TB therapy: not only the bug's fault.Multivalent and Multipathogen Viral Vector Vaccines.Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage.Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.Inhibition of apoptosis by Rv2456c through Nuclear factor-κB extends the survival of Mycobacterium tuberculosis.Expression and role of VLA-1 in resident memory CD8 T cell responses to respiratory mucosal viral-vectored immunization against tuberculosis.CXCR3 Signaling Is Required for Restricted Homing of Parenteral Tuberculosis Vaccine-Induced T Cells to Both the Lung Parenchyma and Airway.Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation.Enhancement of Antituberculosis Immunity in a Humanized Model System by a Novel Virus-Vectored Respiratory Mucosal Vaccine.From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology.Successes and failures in human tuberculosis vaccine development.TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical DevelopmentFrom bench to almost bedside: the long road to a licensed Ebola virus vaccine.Effect of HIV on the Frequency and Number of Mycobacterium tuberculosis-Specific CD4+ T Cells in Blood and Airways During Latent M. tuberculosis Infection.Developments in the formulation and delivery of spray dried vaccines.Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.Reasons for optimism in the search for new vaccines for tuberculosis.
P2860
Q26744622-8641DA4D-313A-4C3C-BAFE-2E4867110440Q26783884-A3440E8E-ECAC-42E3-B784-B8A87086543CQ26796440-E444DE23-9C88-4DE3-B7C8-EF8011D854C6Q27300923-D1DF1E0E-551F-454B-A232-37CC87C3B739Q30375962-0F46CD54-2160-4058-9F5E-3567AC3E9B98Q33637297-28168FBE-62AE-4F6F-864F-B2CA5E177709Q35231023-574A2C58-0D4D-48B1-8F9E-9A18E4CEA6B3Q35772893-9EF573C7-0CAB-4D38-8895-663FA299C198Q35782951-E7B5477F-8BF0-4C6E-8007-40866C8F56BFQ35830513-0AB6BEB1-C508-4D2E-86E7-BC1193982AEDQ35849628-687755D7-7BF5-40F0-8284-7DB5B2A2F13DQ35928588-F3BAEFE1-EC8D-4E7E-8C4A-25C94F688B9EQ35998753-9C85E8AD-102C-479D-A456-61FD44688EBCQ36094215-E4F30436-1812-403A-A1B3-9DFAF3ED8013Q36256304-8A28E5B4-C278-4B68-8788-FEEEA9140B3EQ36287555-D2C75628-9121-4933-B3E1-5E2514FB40D2Q36369598-1E035897-1066-4DE3-983B-E89E6CE5047BQ36838289-6D30DDEC-59DC-48C4-AC81-B5A15C9B0090Q37130796-9329F6C0-3359-49C2-ACC5-E67892DE0B25Q37433271-D3A5DBF2-4E00-4EB4-8ABC-F9BD58619D6BQ38338183-07D1A976-4C10-4186-9190-030FE3FBFACEQ38619090-65E2F0CD-1F66-492E-B686-FAFAF06B1EDAQ38711772-34FE9A16-412D-45A4-AA8A-137E836F8748Q38782463-52374E66-FEF7-4742-85C8-3F4F24FEF76DQ38830323-3FC38C43-7AF6-442D-86CD-407EE7ACC530Q38885257-BF9FE07D-B699-4771-9C37-87F680C1AFEEQ38907507-983D5001-0DC4-47B4-AF0E-39CE60FCE869Q39118925-76FBDA82-9B27-4CC7-8F2B-5CCB2FAC1475Q40069778-07D60270-70F0-453D-842F-27D8CC161D20Q40085228-B00238DE-1D3E-4529-B81B-138CE5F55404Q40106084-B8B84B91-497A-4CA3-AE34-BCD7C59485E9Q40190981-5862873C-1C99-4D06-9D8D-4F634D7B3F43Q40914004-61C80B23-C33C-4259-9740-ECB7C0C2599EQ41996442-B23DA459-AB08-458E-BBA5-0DBD93477DCAQ42372774-274ADB1F-EE4D-445F-BECB-0701E25FAB16Q44106264-1F91F01D-04CE-4830-8A65-A1E6FBCD549DQ46729892-D10BB0D6-9E50-4A4F-BBB4-E255C3629A69Q47106090-AB260972-ED3A-43CA-9F9E-C301465005C5Q47141816-A0D4C0D7-93FD-4753-9B3F-13B061EE3997Q47327109-3D3F2E1A-E512-4413-B114-C6981E551E1C
P2860
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and immunogenicity of a ...... , randomised controlled trial.
@ast
Safety and immunogenicity of a ...... , randomised controlled trial.
@en
Safety and immunogenicity of a ...... , randomised controlled trial.
@nl
type
label
Safety and immunogenicity of a ...... , randomised controlled trial.
@ast
Safety and immunogenicity of a ...... , randomised controlled trial.
@en
Safety and immunogenicity of a ...... , randomised controlled trial.
@nl
prefLabel
Safety and immunogenicity of a ...... , randomised controlled trial.
@ast
Safety and immunogenicity of a ...... , randomised controlled trial.
@en
Safety and immunogenicity of a ...... , randomised controlled trial.
@nl
P2093
P2860
P921
P1476
Safety and immunogenicity of a ...... d, randomised controlled trial
@en
P2093
Henry Bettinson
Iman Satti
Joel Meyer
Mary Smith
Raquel Lopez Ramon
Richard D Antrobus
Rosalind Rowland
Sharon Sheehan
Stephanie A Harris
Zita-Rose Manjaly Thomas
P2860
P304
P356
10.1016/S1473-3099(14)70845-X
P577
2014-08-20T00:00:00Z